Efficacy and survival rate of intensity-modulated radiotherapy combined with chemotherapy for elderly patients with locally advanced oropharyngeal cancer

Feng,Li; Qi,Shummei; Lin,Ming

doi:10.3892/etm.2017.5682

Efficacy and survival rate of intensity-modulated radiotherapy combined with chemotherapy for elderly patients with locally advanced oropharyngeal cancer

Authors:
- Li Feng
- Shummei Qi
- Ming Lin
View Affiliations

Affiliations: Customer Service Management Office, Shandong University Affiliated Jinan Central Hospital, Jinan, Shandong 250013, P.R. China, Department of Stomatology, Jinan Maternity and Child Health Care Hospital, Jinan, Shandong 250001, P.R. China, Department of Stomatology, Shandong University Affiliated Jinan Central Hospital, Jinan, Shandong 250013, P.R. China
Published online on: December 29, 2017 https://doi.org/10.3892/etm.2017.5682
Pages: 2475-2479
Copyright: © Feng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The efficacy of intensity-modulated radiotherapy (IMRT) combined with chemotherapy in the treatment of elderly patients with locally advanced oropharyngeal cancer and its effect on survival rate were studied. Elderly patients (n=150) diagnosed with locally advanced oropharyngeal cancer by histopathology were selected and randomly divided into the observation group (n=75) and the control group (n=75). Patients in the observation group were treated with IMRT combined with chemotherapy, while those in the control group were treated with conventional radiotherapy and chemotherapy. The two groups were treated with docetaxel + cisplatin (TP regimen). All patients received 1 to 2 cycles of docetaxel + cisplatin-induced chemotherapy, and after the radiotherapy began, the chemotherapy with docetaxel was synchronously conducted. The recent efficacy (tumor regression condition was observed at 3 months after the treatment), 1-year, 3-year and 5-year overall survival (OS), local-regional control (LRC), progression-free survival (PFS), disease-free survival (DFS) and the incidence rate of adverse reactions of patients in the two groups were compared. In the observation group, 73 patients completed the radiotherapy and chemotherapy, while all the patients in the control group completed the treatments. The 1-year OS of the observation group and the control group was 97.3 and 85.3%, respectively. In the observation group, the 3-year LRC, OS, PFS and DFS of the observation group was 94.5, 91.8, 90.4 and 87.7%, respectively; the 5-year LRC, OS, PFS and DFS was 64.4, 56.2, 56.2 and 54.8%, respectively. In the control group, the 3-year LRC, OS, PFS and DFS was 86.7, 73.3, 82.7 and 68.0%, respectively; the 5-year LRC, OS, PFS and DFS were 54.7, 45.3, 44.0 and 56.7%, respectively. The differences were statistically significant (P<0.05). In the observation group, the number of leukocytes was decreased, and the incidence rates of acute oropharyngeal mucosa reaction and radiation dermatitis were significantly lower than those in the control group. The differences were statistically significant (P<0.05). In conclusion, IMRT combined with chemotherapy can improve the OS and the 3-year and 5-year LRC, PFS and DFS of elderly patients with locally advanced oropharyngeal cancer, reduce toxic and side effects, and improve patients' quality of life.

View Figures

View References

1	Pinar T, Akdur R, Tuncbilek A, Altundag K and Cengiz M: The relationship between occupations and head and neck cancers. J Natl Med Assoc. 99:64, 68–71. 2007.
2	Harréus U: Surgical errors and risks - the head and neck cancer patient. GMS Curr Top Otorhinolaryngol Head Neck Surg. 12:Doc042013.PubMed/NCBI
3	Kaplan EL: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 9:133–134. 2005.
4	Miah AB, Schick U, Bhide SA, Guerrero-Urbano MT, Clark CH, Bidmead AM, Bodla S, Del Rosario L, Thway K, Wilson P, et al: A phase II trial of induction chemotherapy and chemo-IMRT for head and neck squamous cell cancers at risk of bilateral nodal spread: The application of a bilateral superficial lobe parotid-sparing IMRT technique and treatment outcomes. Br J Cancer. 112:32–38. 2015. View Article : Google Scholar : PubMed/NCBI
5	Nutting C, Harrington K, Rogers MS, Sydenham MA, A'Hern R and Hall M: Results of a phase III multi-centre randomised controlled trial of intensity modulated (IMRT) vs. conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). Clin Oncol. 22:8992009. View Article : Google Scholar
6	Monroe AT, Young JA, Ernster JA, Huff JD and Peddada AV: Acute toxicity of concomitant boost IMRT and chemotherapy for gead and neck cancer in the community setting. Int J Radiat Oncol Biol Phys. 72:S4132008. View Article : Google Scholar
7	Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, et al PARSPORT trial management group, : Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial. Lancet Oncol. 12:127–136. 2011. View Article : Google Scholar : PubMed/NCBI
8	Kreppel M, Eich HT, Kübler A, Zöller JE and Scheer M: Prognostic value of the sixth edition of the UICC's TNM classification and stage grouping for oral cancer. J Surg Oncol. 102:443–449. 2010. View Article : Google Scholar : PubMed/NCBI
9	Yanagawa M, Tatsumi M, Miyata H, Morii E, Tomiyama N, Watabe T, Isohashi K, Kato H, Shimosegawa E, Yamasaki M, et al: Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors. J Nucl Med. 53:872–880. 2012. View Article : Google Scholar : PubMed/NCBI
10	Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC and Lacouture ME: Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events version 4.0. J Am Acad Dermatol. 67:1025–1039. 2012. View Article : Google Scholar : PubMed/NCBI
11	Clavel S, Nguyen DH, Fortin B, Després P, Khaouam N, Donath D, Soulières D, Guertin L and Nguyen-Tan PF: Simultaneous integrated boost using intensity-modulated radiotherapy compared with conventional radiotherapy in patients treated with concurrent carboplatin and 5-fluorouracil for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 82:582–589. 2012. View Article : Google Scholar : PubMed/NCBI
12	Parliament M, Alidrisi M, Munroe M, Wolfaardt J, Scrimger R, Thompson H, Field C, Kurien E and Hanson J: Implications of radiation dosimetry of the mandible in patients with carcinomas of the oral cavity and nasopharynx treated with intensity modulated radiation therapy. Int J Oral Maxillofac Surg. 34:114–121. 2005. View Article : Google Scholar : PubMed/NCBI
13	Yao M, Dornfeld KJ, Buatti JM, Skwarchuk M, Tan H, Nguyen T, Wacha J, Bayouth JE, Funk GF, Smith RB, et al: Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma - the University of Iowa experience. Int J Radiat Oncol Biol Phys. 63:410–421. 2005. View Article : Google Scholar : PubMed/NCBI
14	Huang K, Xia P, Chuang C, Weinberg V, Glastonbury CM, Eisele DW, Lee NY, Yom SS, Phillips TL and Quivey JM: Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: The University of California-San Francisco experience. Cancer. 113:497–507. 2008. View Article : Google Scholar : PubMed/NCBI
15	Daly ME, Le QT, Maxim PG, Loo BW Jr, Kaplan MJ, Fischbein NJ, Pinto H and Chang DT: Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: Clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys. 76:1339–1346. 2010. View Article : Google Scholar : PubMed/NCBI
16	Monnerat C, Faivre S, Temam S, Bourhis J and Raymond E: End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol. 13:995–1006. 2002. View Article : Google Scholar : PubMed/NCBI
17	Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, et al EORTC 24971/TAX 323 Study Group, : Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 357:1695–1704. 2007. View Article : Google Scholar : PubMed/NCBI
18	Rosenthal DI, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, Garden AS, Kuettel MR, Sidhu K, Schultz CJ, et al: Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: Report of the phase II trial RTOG 0024. J Clin Oncol. 27:4727–4732. 2009. View Article : Google Scholar : PubMed/NCBI
19	Balukrishna S, Pilaka VKR, Michael RC, Samuel P and Ravindran PB: Hyper-fractionated intensity modulated radiation therapy (HF-IMRT) in head and neck cancer: The technical feasibility and results of a short clinical series. J Clin Diagn Res. 9:XR01–XR04. 2015.PubMed/NCBI
20	Wahl RL, Jacene H, Kasamon Y and Lodge MA: From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 50 Suppl 1:122S–150S. 2009. View Article : Google Scholar : PubMed/NCBI
21	Hoeller U, Tribius S, Kuhlmey A, Grader K, Fehlauer F and Alberti W: Increasing the rate of late toxicity by changing the score? A comparison of RTOG/EORTC and LENT/SOMA scores. Int J Radiat Oncol Biol Phys. 55:1013–1018. 2003. View Article : Google Scholar : PubMed/NCBI
22	Kelly JR, Husain ZA and Burtness B: Treatment de-intensification strategies for head and neck cancer. Eur J Cancer. 68:125–133. 2016. View Article : Google Scholar : PubMed/NCBI